** AIM Vaccine 6660.HK soars as much as 10.1% to HK$6.09; on course for biggest one-day pct gain since Nov. 1, 2024
** Stock hits highest since Jan. 2 on second consecutive session of gains
** Co submits application for clinical trial of mRNA RSV (respiratory syncytial virus) vaccines to U.S. FDA
** Says preclinical animal tests results showed that humoral and cellular immunity of its mRNA RSV vaccine significantly higher than those of internationally marketed products
** Adds industry consultant expects RSV vaccines' global market size to reach $16.7 bln by 2030 from $2.46 bln in 2023
** RSV is a common respiratory tract infection pathogen, which is highly contagious and widely prevalent
** Stock fell 21.8% last year
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.